42 159

Cited 3 times in

Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice

Authors
 Da Hea Seo  ;  Young Ju Suh  ;  Yongin Cho  ;  Seong Hee Ahn  ;  Seongha Seo  ;  Seongbin Hong  ;  Yong-Ho Lee  ;  Young Ju Choi  ;  Eunjig Lee  ;  So Hun Kim 
Citation
 YONSEI MEDICAL JOURNAL, Vol.63(9) : 825-833, 2022-09 
Journal Title
YONSEI MEDICAL JOURNAL
ISSN
 0513-5796 
Issue Date
2022-09
MeSH
Benzhydryl Compounds ; Blood Glucose ; Body Weight ; Diabetes Mellitus, Type 2* ; Double-Blind Method ; Drug Therapy, Combination ; Glucosides ; Glycated Hemoglobin ; Humans ; Hypoglycemic Agents ; Metformin* ; Pyrimidines ; Republic of Korea ; Thiazolidinediones ; Treatment Outcome
Keywords
Diabetes mellitus, type 2 ; sodium-glucose transporter 2 inhibitors ; thiozolidinediones
Abstract
Purpose: This study aimed to evaluate the efficacy and tolerability of dapagliflozin as an add-on or a switch therapy to lobeglitazone plus metformin (MFM) in Korean patients with inadequately controlled type 2 diabetes mellitus (T2DM) in real-world clinical practice.

Materials and methods: The study included 109 patients who started dapagliflozin as add-on or switch therapy to lobeglitazone plus MFM. The primary outcome was a change in glycated hemoglobin (HbA1c) level from baseline after 12 months of treatment. Secondary outcomes included changes in fasting plasma glucose (FPG), lipid profiles, body weight, visceral fat area (VFA), and blood pressure after 12 months of treatment.

Results: The baseline HbA1c was 8.3±1.3% (8.7±1.5% in the add-on group and 8.1±1.0% in the switch group). After 12 months, mean HbA1c decreased (-0.91%) in all patients (p<0.05) (-1.39% in the add-on group and -0.63% in the switch group). Significant reductions in FPG were also observed in both the add-on and switch groups (-54.37 mg/dL and -24.68 mg/dL, respectively). Overall, there was a significant improvement in serum triglyceride (-24.74 mg/dL), low density lipoprotein cholesterol (-7.92 mg/dL), body weight (-2.98 kg), VFA (-9.00 cm²), and systolic blood pressure (-8.67 mm Hg). Approximately 35.8% of patients achieved HbA1c <7.0% after 12 months.

Conclusion: Dapagliflozin, as an add-on or a switch therapy to lobeglitazone plus MFM, can be a suitable alternative for Korean patients with inadequately controlled T2DM. The combination therapy resulted in significant reductions in HbA1c levels, body weight, and blood pressure.
Files in This Item:
T9992022635.pdf Download
DOI
10.3349/ymj.2022.63.9.825
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Yong Ho(이용호) ORCID logo https://orcid.org/0000-0002-6219-4942
Lee, Eun Jig(이은직) ORCID logo https://orcid.org/0000-0002-9876-8370
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/193406
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links